<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font20 { font-size : 20; } .font25 { font-size : 25; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font25">and </span>
   <span class="font20">LA-ART </span>
   <span class="font17">ART </span>
   <span class="font17">AYA </span>
   <span class="font16">oral </span>
   <span class="font16">HIV </span>
   <span class="font15">for </span>
   <span class="font15">cost </span>
   <span class="font14">with </span>
   <span class="font13">are </span>
   <span class="font13">from </span>
   <span class="font13">{background </span>
   <span class="font12">[]. </span>
   <span class="font12">adherence </span>
   <span class="font12">per </span>
   <span class="font12">drug </span>
   <span class="font12">viral </span>
   <span class="font12">who </span>
   <span class="font12">suppression </span>
   <span class="font12">margin </span>
   <span class="font12">long-acting </span>
   <span class="font12">{border-style </span>
   <span class="font12">costs </span>
   <span class="font12">this </span>
   <span class="font12">were </span>
   <span class="font12">would </span>
   <span class="font11">have </span>
   <span class="font11">px;} </span>
   <span class="font11">switch </span>
   <span class="font11">that </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">Kenya </span>
   <span class="font11">may </span>
   <span class="font11">model </span>
   <span class="font11">under </span>
   <span class="font11">cost-effective </span>
   <span class="font11">health </span>
   <span class="font11">study </span>
   <span class="font11">than </span>
   <span class="font11">increase </span>
   <span class="font11">not </span>
   <span class="font11">The </span>
   <span class="font11">annual </span>
   <span class="font11">maximum </span>
   <span class="font11">[], </span>
   <span class="font11">adults </span>
   <span class="font11">antiretroviral </span>
   <span class="font11">considered </span>
   <span class="font11">incremental </span>
   <span class="font11">threshold </span>
   <span class="font11">among </span>
   <span class="font11">LA-ART. </span>
   <span class="font11">assumed </span>
   <span class="font11">clinical </span>
   <span class="font11">current </span>
   <span class="font11">lower </span>
   <span class="font11">will </span>
   <span class="font11">Health </span>
   <span class="font11">administration </span>
   <span class="font11">cost-effectiveness </span>
   <span class="font11">due </span>
   <span class="font11">population </span>
   <span class="font11">population. </span>
   <span class="font11">proportion </span>
   <span class="font11">results </span>
   <span class="font11">sexual </span>
   <span class="font11">was </span>
   <span class="font11">which </span>
   <span class="font10">ART, </span>
   <span class="font10">Our </span>
   <span class="font10">adolescents </span>
   <span class="font10">can </span>
   <span class="font10">care </span>
   <span class="font10">daily </span>
   <span class="font10">has </span>
   <span class="font10">non-adherent </span>
   <span class="font10">over </span>
   <span class="font10">using </span>
   <span class="font10">virally </span>
   <span class="font10">â€" </span>
   <span class="font10">LA-ART, </span>
   <span class="font10">all </span>
   <span class="font10">averted </span>
   <span class="font10">higher </span>
   <span class="font10">impact </span>
   <span class="font10">induction </span>
   <span class="font10">likely </span>
   <span class="font10">only </span>
   <span class="font10">px; </span>
   <span class="font10">suppressed </span>
   <span class="font10">those </span>
   <span class="font10">transmission </span>
   <span class="font10">treatment </span>
   <span class="font10">{font-family </span>
   <span class="font10">ART. </span>
   <span class="font10">This </span>
   <span class="font10">age </span>
   <span class="font10">associated </span>
   <span class="font10">base </span>
   <span class="font10">been </span>
   <span class="font10">currently </span>
   <span class="font10">data </span>
   <span class="font10">estimated </span>
   <span class="font10">font-size </span>
   <span class="font10">infections </span>
   <span class="font10">injectable </span>
   <span class="font10">mathematical </span>
   <span class="font10">number </span>
   <span class="font10">scenario </span>
   <span class="font10">therapy </span>
   <span class="font10">time </span>
   <span class="font10">young </span>
   <span class="font10">-week </span>
   <span class="font10">AIDS </span>
   <span class="font10">HIV-positive </span>
   <span class="font10">However, </span>
   <span class="font10">Kenya's </span>
   <span class="font10">additional </span>
   <span class="font10">adult </span>
   <span class="font10">analyses </span>
   <span class="font10">benefits </span>
   <span class="font10">compared </span>
   <span class="font10">could </span>
   <span class="font10">double; </span>
   <span class="font10">economic </span>
   <span class="font10">improve </span>
   <span class="font10">including </span>
   <span class="font10">less </span>
   <span class="font10">more </span>
   <span class="font10">most </span>
   <span class="font10">need </span>
   <span class="font10">new </span>
   <span class="font10">non-adherence </span>
   <span class="font10">our </span>
   <span class="font10">patients </span>
   <span class="font10">period </span>
   <span class="font10">priority </span>
   <span class="font10">rate </span>
   <span class="font10">receiving </span>
   <span class="font10">resistance </span>
   <span class="font10">risk </span>
   <span class="font10">should </span>
   <span class="font10">studies </span>
   <span class="font10">trials </span>
   <span class="font10">â€¢ </span>
   <span class="font10">Acquir </span>
   <span class="font10">Adolescents </span>
   <span class="font10">Antiretroviral </span>
   <span class="font10">Costs </span>
   <span class="font10">Defic </span>
   <span class="font10">Fig. </span>
   <span class="font10">HIV-related </span>
   <span class="font10">ICER </span>
   <span class="font10">Immune </span>
   <span class="font10">Long-acting </span>
   <span class="font10">Maximum </span>
   <span class="font10">Table </span>
   <span class="font10">U.S. </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">changes </span>
   <span class="font10">conducted </span>
   <span class="font10">coverage </span>
   <span class="font10">high </span>
   <span class="font10">individuals </span>
   <span class="font10">mortality </span>
   <span class="font10">other </span>
   <span class="font10">overall </span>
   <span class="font10">prevalence </span>
   <span class="font10">solid; </span>
   <span class="font10">sub-Saharan </span>
   <span class="font10">therefore </span>
   <span class="font10">varied </span>
   <span class="font10">year </span>
   <span class="font10">years </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">â€¢% </span>
   <span class="font10">(LA-ART) </span>
   <span class="font10">(oral </span>
   <span class="font10">(â€¢%) </span>
   <span class="font10">Accessed </span>
   <span class="font10">For </span>
   <span class="font10">HIV- </span>
   <span class="font10">Int </span>
   <span class="font10">LATTE- </span>
   <span class="font10">Phase </span>
   <span class="font10">Sensitivity </span>
   <span class="font10">adapted </span>
   <span class="font10">addition </span>
   <span class="font10">also </span>
   <span class="font10">analysis </span>
   <span class="font10">article </span>
   <span class="font10">assumes </span>
   <span class="font10">available </span>
   <span class="font10">average </span>
   <span class="font10">barriers </span>
   <span class="font10">bold </span>
   <span class="font10">both </span>
   <span class="font10">but </span>
   <span class="font10">capita </span>
   <span class="font10">case </span>
   <span class="font10">cost-effective. </span>
   <span class="font10">count </span>
   <span class="font10">courier; </span>
   <span class="font10">decrease </span>
   <span class="font10">double </span>
   <span class="font10">effective </span>
   <span class="font10">em; </span>
   <span class="font10">evaluated </span>
   <span class="font10">evaluation </span>
   <span class="font10">found </span>
   <span class="font10">include </span>
   <span class="font10">included </span>
   <span class="font10">infection </span>
   <span class="font10">interest </span>
   <span class="font10">intervention </span>
   <span class="font10">living </span>
   <span class="font10">low </span>
   <span class="font10">per-person </span>
   <span class="font10">phase </span>
   <span class="font10">population, </span>
   <span class="font10">population-level </span>
   <span class="font10">potential </span>
   <span class="font10">projected </span>
   <span class="font10">pt;} </span>
   <span class="font10">rates </span>
   <span class="font10">regimens </span>
   <span class="font10">reporting </span>
   <span class="font10">rilpivirine </span>
   <span class="font10">role </span>
   <span class="font10">scenario, </span>
   <span class="font10">school </span>
   <span class="font10">take </span>
   <span class="font10">taking </span>
   <span class="font10">their </span>
   <span class="font10">thresholds </span>
   <span class="font10">two-month </span>
   <span class="font10">uptake </span>
   <span class="font10">Î¼L </span>
  </p>
 </body>
</html>
